Request a Demo or Get Help

Journals Citing Studylog

Studylog has been featured in such publications as the following:

Electrospray-Induced Mass Spectrometry Is Not Suitable for Determination of Peptidic Cu(II) Complexes

Dawid Plonka, Radoslaw Kotuniak, Katarzyna Dabrowska, etc. J Am Soc Mass Spectrom. 2021 Dec 1; 32(12): 2766–2776.

ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide

Lara H. El Touny, Curtis Hose, John Connelly, etc. Oncotarget. 2021 Oct 12; 12(21): 2114–2130.

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill, etc. Nat Cancer. 2021 Oct; 2(10): 1002–1017.

download-12

A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity

Fanying Meng, Wan-Fen Li, Donald Jung, etc. Am J Cancer Res. 2021; 11(7): 3645–3659.

ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition

Mark G. Anderson, Qian Zhang, Luis E. Rodriguez, etc. BMC Cancer. 2021; 21: 681.

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)

Moshe Lapidot, Abigail E. Case, Ellen L. Weisberg, etc. Br J Cancer. 2021 Aug 17; 125(4): 582–592.

download-7

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers

Avisek Majumder, Manbir Sandhu, Debarko Banerji, etc. Sci Rep. 2021; 11: 9091.

m_molcanther_20_4_cover

F-aza-T-dCyd (NSC801845), a novel cytidine analog, in comparative cell culture and xenograft studies with the clinical candidates T-dCyd, F-T-dCyd and aza-T-dCyd

Joel Morris, Donn G. Wishka, Omar D. Lopez, etc. Mol Cancer Ther. 2021 Apr; 20(4): 625–631.

Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes

Juan A. Marín-Jiménez, Anna Capasso, Matthew S. Lewis, etc. Front Immunol. 2021; 12: 607282.

CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression

Amlan Das, Inamul Haque, Priyanka Ray, etc. Pharmacol Res Perspect. 2021 Apr; 9(2): e00753.

Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors

Christoph Grohmann, Francesca Walker, Mark Devlin, etc. Cell Death Dis. 2021 Mar; 12(3): 268.

Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours

Silpa Gampala, Fenil Shah, Chi Zhang, etc, Br J Cancer. 2021 Apr 27; 124(9): 1566–1580.

CENP-A overexpression promotes aneuploidy with karyotypic heterogeneity

Roshan L. Shrestha, Austin Rossi, Darawalee Wangsa, etc. J Cell Biol. 2021 Apr 5; 220(4): e202007195.

Symptom perception and functioning in patients with advanced cancer

Eun Joo Yang, Keun Seok Lee, Myong Cheol Lim, etc. PLoS One. 2021; 16(2): e0245987.

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade

Kartik Sehgal, Andrew Portell, Elena V. Ivanova, etc. J Clin Invest. 2021 Jan 19; 131(2): e135038.

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

Darren J. Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, etc. MAbs. 2021; 13(1): 1857100.

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)

Moshe Lapidot, Abigail E. Case, Dalia Larios, etc. Cancers (Basel). 2021 Jan; 13(1): 7.

A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity

Jonathan Rios-Doria, Margaret Favata, Kerri Lasky, etc. Front Oncol. 2020; 10: 598477.

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer

Goldie Y.L. Lui, Reid Shaw, Franz X. Schaub, etc. EBioMedicine. 2020 Oct; 60: 102988.

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancerThis is the heading

Neil A. O’Brien, Martina S. J. McDermott, Dylan Conklin, etc. Breast Cancer Res. 2020; 22: 89.

Page 2